We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.16 | -0.41% | 38.66 | 39.115 | 38.61 | 39.04 | 3,851,914 | 01:00:00 |
From Oct 2019 to Oct 2024
By Adriano Marchese
AnaptysBio Inc. said Thursday that the U.S. Food and Drug Administration approved GlaxoSmithKline PLC's biologics license application for JEMPERLI, a treatment for endometrial cancer.
The clinical-stage biotechnology company said JEMPERLI, also known as dostarlimab-gxly, was generated by AnaptysBio and developed by TESARO Inc.--now a part of GSK--under a collaboration agreement.
AnaptysBio received a $20 million milestone payment as part of the approval.
A Biologics License Application for JEMPERLI--a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer--is needed to obtain permission for distribution across U.S. states.
"This event provides important validation for our proprietary SHM antibody discovery platform and provides significant potential future milestone and royalty revenue to support AnaptysBio's growth," President and Chief Executive Hamza Suria said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 22, 2021 17:04 ET (21:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
